SCHEMBL3465166

SCHEMBL3465166

CSc1cc2c(cc1Sc1nc(C(N)=O)c(N)n1C)CCO2

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 4/20 0.38
HSP90AB1 P08238 3/20 0.38
PLAU P00749 1/20 0.33
RAB9A P51151 3/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 1/20 0.32
DYRK1A Q13627 1/20 0.32
NPC1 O15118 2/20 0.31
PLA2G10 O15496 1/20 0.31
CCNA2 P20248 1/20 0.31
CDK2 P24941 1/20 0.31
PLK1 P53350 1/20 0.31
CCNA1 P78396 1/20 0.31
PLK3 Q9H4B4 1/20 0.31
PLK2 Q9NYY3 1/20 0.31
CHEK1 O14757 1/20 0.30
MAP3K14 Q99558 1/20 0.30
CLK1 P49759 1/20 0.30
PI4K2A Q9BTU6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3464730 0.89 HSP90AA1 (0.40) HSP90AA1HSP90AB1
SCHEMBL3463800 0.88 HSP90AA1 (0.44) HSP90AA1HSP90AB1
SCHEMBL3464443 0.76 HSP90AA1 (0.49) HSP90AA1HSP90AB1
SCHEMBL3464733 0.76 HSP90AA1 (0.45) HSP90AA1HSP90AB1
SCHEMBL3465280 0.75 HSP90AA1 (0.38) HSP90AA1HSP90AB1
SCHEMBL3465405 0.74 HSP90AA1 (0.35) HSP90AA1HSP90AB1
SCHEMBL3465317 0.74 HSP90AA1 (0.43) HSP90AA1HSP90AB1
SCHEMBL3465443 0.72 HSP90AA1 (0.38) HSP90AA1HSP90AB1RAB9ANPC1
SCHEMBL3465233 0.71 PI4K2A (0.32) HSP90AA1HSP90AB1PLAUDYRK1AMAP3K14
SCHEMBL3464797 0.70 KDM4E (0.42) HSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100240656-A1 COMPOUNDS AS HSP90 INHIBITORS ORYZON GENOMICS, S.A. (ES) 2010-09-23 US claimed
US-20100240656-A1 COMPOUNDS AS HSP90 INHIBITORS ORYZON GENOMICS, S.A. (ES) 2010-09-23 US disclosed
US-20100240656-A1 COMPOUNDS AS HSP90 INHIBITORS ORYZON GENOMICS, S.A. (ES) 2010-09-23 US disclosed
US-20100240656-A1 COMPOUNDS AS HSP90 INHIBITORS ORYZON GENOMICS, S.A. (ES) 2010-09-23 US disclosed
WO-2009007399-A1 NEW COMPOUNDS AS HSP90 INHIBITORS CRYSTAX PHARMACEUTICALS, S.L. (ES) 2009-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240656-A1 COMPOUNDS AS HSP90 INHIBITORS HSP90AB1, HSP90AB2P, HSP90AA1 HSP90AA1 3/4885HSP90AB1 1/4885PLAU 4872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.